Literature DB >> 32973344

Hypophosphatasia: a genetic-based nosology and new insights in genotype-phenotype correlation.

Etienne Mornet1, Agnès Taillandier2, Christelle Domingues2, Annika Dufour2, Emmanuelle Benaloun2, Nicole Lavaud2, Fabienne Wallon2, Nathalie Rousseau2, Carole Charle2, Mihelaiti Guberto2, Christine Muti2, Brigitte Simon-Bouy2.   

Abstract

Hypophosphatasia (HPP) is caused by pathogenic variants in the ALPL gene. There is a large continuum in the severity, ranging from a lethal perinatal form to dental issues. We analyzed a cohort of 424 HPP patients from European geographic origin or ancestry. Using 3D modeling and results of functional tests we classified ALPL pathogenic variants according to their dominant negative effect (DNE) and their severity. The cohort was described by the genotypes resulting from alleles s (severe recessive), Sd (severe dominant), and m (moderate). Many recurrent variants showed a regional anchor pointing out founder effects rather than multiple mutational events. Homozygosity was an aggravating factor of the severity and moderate alleles were rare both in number and frequency. Pathogenic variants with DNE were found in both recessive and dominant HPP. Sixty percent of the adults tested were heterozygous for a variant showing no DNE, suggesting another mechanism of dominance like haploinsufficiency. Adults with dominant HPP without DNE were found statistically less severely affected than adults with DNE variants. Adults with dominant HPP without DNE represent a new clinical entity mostly diagnosed from 2010s, characterized by nonspecific signs of HPP and low alkaline phosphatase, and for which a high prevalence is expected. In conclusion, the genetic composition of our cohort suggests a nosology with 3 clinical forms: severe HPP is recessive and rare, moderate HPP is recessive or dominant and more common, and mild HPP, characterized by low alkaline phosphatase and unspecific clinical signs, is dominantly inherited and very common.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32973344      PMCID: PMC7868366          DOI: 10.1038/s41431-020-00732-6

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  42 in total

1.  Hypophosphatasia.

Authors:  D FRASER
Journal:  Am J Med       Date:  1957-05       Impact factor: 4.965

2.  Genetics of hypophosphatasia.

Authors:  E Mornet
Journal:  Arch Pediatr       Date:  2017-05       Impact factor: 1.180

3.  A molecular-based estimation of the prevalence of hypophosphatasia in the European population.

Authors:  Etienne Mornet; Alice Yvard; Agnes Taillandier; Delphine Fauvert; Brigitte Simon-Bouy
Journal:  Ann Hum Genet       Date:  2011-03-24       Impact factor: 1.670

4.  Hypophosphatasia: validation and expansion of the clinical nosology for children from 25 years experience with 173 pediatric patients.

Authors:  Michael P Whyte; Fan Zhang; Deborah Wenkert; William H McAlister; Karen E Mack; Marci C Benigno; Stephen P Coburn; Susan Wagy; Donna M Griffin; Karen L Ericson; Steven Mumm
Journal:  Bone       Date:  2015-02-27       Impact factor: 4.398

Review 5.  Hypophosphatasia: the mutations in the tissue-nonspecific alkaline phosphatase gene.

Authors:  E Mornet
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

6.  Enzyme-replacement therapy in life-threatening hypophosphatasia.

Authors:  Michael P Whyte; Cheryl R Greenberg; Nada J Salman; Michael B Bober; William H McAlister; Deborah Wenkert; Bradley J Van Sickle; Jill H Simmons; Terence S Edgar; Martin L Bauer; Mohamed A Hamdan; Nick Bishop; Richard E Lutz; Mairead McGinn; Stanley Craig; Jean N Moore; John W Taylor; Robert H Cleveland; William R Cranley; Ruth Lim; Tom D Thacher; Jill E Mayhew; Matthew Downs; José Luis Millán; Alison M Skrinar; Philippe Crine; Hal Landy
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

Review 7.  Hypophosphatasia.

Authors:  Agnès Linglart; Martin Biosse-Duplan
Journal:  Curr Osteoporos Rep       Date:  2016-06       Impact factor: 5.096

Review 8.  Hypophosphatasia.

Authors:  Etienne Mornet
Journal:  Metabolism       Date:  2017-09-20       Impact factor: 8.694

Review 9.  Hypophosphatasia: An overview For 2017.

Authors:  Michael P Whyte
Journal:  Bone       Date:  2017-02-24       Impact factor: 4.398

Review 10.  Hypophosphatasia.

Authors:  Etienne Mornet
Journal:  Orphanet J Rare Dis       Date:  2007-10-04       Impact factor: 4.123

View more
  14 in total

Review 1.  [Rare bone disorders and respective treatments].

Authors:  Lothar Seefried; Franz Jakob
Journal:  Internist (Berl)       Date:  2021-03-29       Impact factor: 0.743

Review 2.  Proposing a clinical algorithm for better diagnosis of hypophosphatasia in resource-limiting situations.

Authors:  Sreyanko Sadhukhan; Poonam Mehta; Singh Rajender; Sushil Kumar Gupta; Naibedya Chattopadhyay
Journal:  Osteoporos Int       Date:  2022-07-01       Impact factor: 4.507

3.  Biochemical and clinical manifestations in adults with hypophosphatasia: a national cross-sectional study.

Authors:  Nicola Hepp; Anja Lisbeth Frederiksen; Morten Duno; Niklas Rye Jørgensen; Jens-Erik Beck Jensen
Journal:  Osteoporos Int       Date:  2022-08-19       Impact factor: 5.071

Review 4.  Dental manifestation and management of hypophosphatasia.

Authors:  Rena Okawa; Kazuhiko Nakano
Journal:  Jpn Dent Sci Rev       Date:  2022-07-02

5.  Characterization of Genetic Variants of Uncertain Significance for the ALPL Gene in Patients With Adult Hypophosphatasia.

Authors:  Raquel Sanabria-de la Torre; Luis Martínez-Heredia; Sheila González-Salvatierra; Francisco Andújar-Vera; Iván Iglesias-Baena; Juan Miguel Villa-Suárez; Victoria Contreras-Bolívar; Mario Corbacho-Soto; Gonzalo Martínez-Navajas; Pedro J Real; Cristina García-Fontana; Manuel Muñoz-Torres; Beatriz García-Fontana
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-14       Impact factor: 6.055

Review 6.  Hypophosphatasia: A Unique Disorder of Bone Mineralization.

Authors:  Juan Miguel Villa-Suárez; Cristina García-Fontana; Francisco Andújar-Vera; Sheila González-Salvatierra; Tomás de Haro-Muñoz; Victoria Contreras-Bolívar; Beatriz García-Fontana; Manuel Muñoz-Torres
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

7.  Evaluation of alveolar bone hypomineralization in pediatric hypophosphatasia using orthopantomography.

Authors:  Rena Okawa; Takashi Nakamoto; Saaya Matayoshi; Kazuhiko Nakano; Naoya Kakimoto
Journal:  Sci Rep       Date:  2022-01-24       Impact factor: 4.996

8.  Prevalence of low alkaline phosphatase activity in laboratory assessment: Is hypophosphatasia an underdiagnosed disease?

Authors:  Tobias Schmidt; Constantin Schmidt; Michael Amling; Jan Kramer; Florian Barvencik
Journal:  Orphanet J Rare Dis       Date:  2021-10-28       Impact factor: 4.123

Review 9.  Hypophosphatasia.

Authors:  Symeon Tournis; Maria P Yavropoulou; Stergios A Polyzos; Artemis Doulgeraki
Journal:  J Clin Med       Date:  2021-12-01       Impact factor: 4.241

10.  Biochemical, clinical and genetic characteristics in adults with persistent hypophosphatasaemia; Data from an endocrinological outpatient clinic in Denmark.

Authors:  Nicola Hepp; Anja Lisbeth Frederiksen; Morten Duno; Jakob Præst Holm; Niklas Rye Jørgensen; Jens-Erik Beck Jensen
Journal:  Bone Rep       Date:  2021-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.